Skip Navigation

Annals of Oncology 2009 20(2):195; doi:10.1093/annonc/mdn790
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in Ann Oncol
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

in this issue

in this issue

The first 10% of the full text of this article appears below.


   Long-term prediction by clinicopathological risk classification algorithms in node-negative breast
 
Consensus recommendations now propose adjuvant systemic therapy for virtually all breast cancer patients, yet the potential adverse effects of adjuvant therapy can negatively affect quality of life. In order to avoid overtreatment as well as undertreatment, the appropriate treatment strategy must be selected on the basis of careful risk assessment for each individual patient. The single most important histopathological factor for risk stratification in primary breast cancer is nodal status. . . . [Full Text of this Article]


   Secondary cytoreduction in the management of relapsed epithelial ovarian cancer
 

   False-positive PET scans in patients with aggressive NHL treated with rituximab
 

   The length of consent documents in oncology trials
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in Ann Oncol:

Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer—comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial
M. Schmidt, A. Victor, D. Bratzel, D. Boehm, C. Cotarelo, A. Lebrecht, W. Siggelkow, J. G. Hengstler, A. Elsäßer, M. Gehrmann, H. -A. Lehr, H. Koelbl, G. von Minckwitz, N. Harbeck, and C. Thomssen
Ann Oncol 2009 20: 258-264. [Abstract] [Full Text]  

The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer
H. Oksefjell, B. Sandstad, and C. Tropé
Ann Oncol 2009 20: 286-293. [Abstract] [Full Text]  

High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens
H. S. Han, M. P. Escalón, B. Hsiao, A. Serafini, and I. S. Lossos
Ann Oncol 2009 20: 309-318. [Abstract] [Full Text]  

The length of consent documents in oncological trials is doubled in twenty years
O. Berger, B. H. Grønberg, K. Sand, S. Kaasa, and J. H. Loge
Ann Oncol 2009 20: 379-385. [Abstract] [Full Text]